#Italy #Milan #MMA #Genespire #SR-TIGET

Promising Steps in Gene Therapy: Genespire and SR-TIGET

In a remarkable breakthrough in the field of gene therapy, Genespire, alongside researchers from the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has unveiled compelling preclinical data that points to the effectiveness of their liver-directed immune-shielded lentiviral gene therapy for treating methylmalonic acidemia (MMA). This genetic disorder, marked by a deficiency of the enzyme methylmalonyl-CoA mutase, impedes the body's ability to metabolize certain fats and proteins, leading to potentially life-threatening complications.

Groundbreaking Study Findings

The pivotal study, documented in the Journal of Hepatology, demonstrates that delivering the MMUT gene through a single systemic administration of a lentiviral vector resulted in significant and enduring therapeutic benefits in mouse models afflicted by MMA. The treatment not only surpassed an impressive 80% transfer efficiency to the liver but also showed durability by leading to sustained improvements throughout the mice's average lifespan. The significance of this is profound, as the results indicate that the gene therapy may continue to be effective as the liver matures postnatally.

Understanding Methylmalonic Acidemia

Methylmalonic acidemia is a rare genetic condition that's often caused by a mutation in the gene responsible for producing the vital enzyme, methylmalonyl-CoA mutase. Without this enzyme, the body starts to accumulate toxic metabolites, severely compromising organ function and causing various metabolic crises, growth retardation, and neurological impairments. As it stands, patients grappling with MMA endure high morbidity rates and greatly diminished lifespans, with no targeted pharmaceutical solutions currently available.

Advancements and Future Directions

Within the study, researchers advanced their methodology by administering an optimized dose that included a refined variant of the MMUT transgene, which resulted in improved therapeutic outcomes. Remarkably, this version showcased a dose-dependent enhancement of metabolomic biomarkers, which underscores the potential for a gradual elevation of therapeutic efficacy, especially as genetically corrected cells could gradually replace diseased ones in the liver over time.

Lucia Faccio, CEO of Genespire, commented on the promising findings, stating, "These results affirm our commitment to advancing our lead asset for MMA, GENE202, towards clinical trials. We are optimistic about the possible impact of our research on patients' health and are grateful for the contributions of all involved in this study, especially our partners at SR-TIGET."

Dr. Alessio Cantore, a prominent figure at SR-TIGET, echoed these sentiments by highlighting the comprehensive preclinical data that supports the initiation of clinical trials targeting pediatric MMA patients. His leadership in this study, combined with the evidence presented, showcases a hopeful future for those affected by this challenging condition.

Conclusion

The collaboration between Genespire and SR-TIGET is paving the way for innovative treatments against MMA. By utilizing an advanced gene therapy approach, they are not only working toward potentially groundbreaking solutions for patients but are also addressing significant unmet medical needs within genetic medicine. With continued research and dedication, there’s hope for a future where a single administration could yield substantial and lasting health improvements for affected individuals.

For more information, you can access the full paper at Journal of Hepatology.

About Genespire

Genespire is at the forefront of biotechnology, focusing on developing off-the-shelf immune-shielded gene therapies, particularly for genetic disorders affecting children. Through their innovative lentiviral vector technologies, they aim to facilitate lifelong therapy production directly from patients' livers. As a spin-off from the distinguished SR-TIGET institute, Genespire is committed to addressing unmet medical needs in inherited metabolic disorders.

About SR-TIGET

The San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) is a globally recognized institution based in Milan, Italy, dedicated to advancing gene and cell therapy research. Founded in 1996, it has established itself as a cornerstone for innovation and excellence in the clinical application of genetic therapies.